Immunoglobulin light chain-derived amyloid fibril

Immunoglobulin light chain-derived amyloid fibril is an aggregated, misfolded protein structure formed from fragments of immunoglobulin light chains, which are normally components of antibodies. In AL (amyloid light chain) amyloidosis, abnormal clonal plasma cells overproduce monoclonal light chains, which circulate, misfold, and aggregate into amyloid fibrils. These fibrils are insoluble, deposit in various organs (especially the heart, kidneys, liver, and nerves), and cause progressive and often fatal dysfunction[1][2][3][4][5][6]. The fibrils themselves are not enzymes, receptors, transporters, or similar classical drug targets. Instead, they are the pathological end products of a plasma cell dyscrasia. Drug interventions in AL amyloidosis do not target the fibril structure directly, but rather the production of light chains by the underlying abnormal plasma cells. The immunoglobulin light chain precursor belongs to the immunoglobulin superfamily and exhibits high sequence variability. The amyloidogenic potential is both sequence- and mutation-dependent[2][3][4]. **Note:** - “Immunoglobulin light chain-derived amyloid fibril” is a description of a pathological aggregate, not a druggable target like an enzyme or receptor; thus, is_target = false, is_incorrect = true (for purposes of therapeutic target databases). - Drugs interact with the pathological process via upstream cell targets (plasma cells), not the fibrils themselves. - Canonical target name would typically refer to "Immunoglobulin light chain" or, more specifically, to the abnormal plasma cell clone. If you require structured data for the precursor protein or cellular source (e.g., "Immunoglobulin light chain" or "Plasma cell immunoglobulin light chain"), please clarify.

Other names

AL amyloid fibrilamyloid light chain fibrilAL fibrillight chain amyloid fibrilamyloid derived from immunoglobulin light chain

Inhibition of light chain production (by targeting plasma cells or B cells); Reduction of amyloid formation or removal of existing deposits (experimental therapies)